Reference health
Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China
1 of 33 checkable references need attention · checked 2026-07-23
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.3233/CLO-2009-0497
The 32 checked references that resolve
resolves10.1007/s00428-010-0952-2
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
resolves10.1200/JCO.2010.33.6313
Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
resolves10.1245/s10434-007-9771-3
EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases
resolves10.1038/sj.bjc.6602184
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
resolves10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
resolves10.1016/S0305-7372(10)70014-1
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
resolves10.1093/annonc/mdn169
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
resolves10.1200/JCO.2013.48.9070
Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
resolves10.7150/jca.4090
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
resolves10.1007/s13277-014-1636-3
Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature
resolves10.1007/s13277-014-1693-7
Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis
resolves10.1007/s13277-014-1871-7
Comment on Gu et al. entitled “Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis”
resolves10.1245/s10434-010-0985-4
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
resolves10.1186/s40880-015-0042-6
The updated incidences and mortalities of major cancers in China, 2011
resolves10.1007/s12094-011-0637-6
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
resolves10.1007/s13277-014-2481-0
Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer
resolves10.1007/s00432-009-0574-8
Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance
resolves10.1002/ijc.26292
Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review
resolves10.1111/j.1365-2559.2008.03028.x
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
resolves10.1093/annonc/mdi064
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
resolves10.5858/arpa.2011-0168-RS
HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications
resolves10.1245/aso.2003.05.010
Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer
resolves10.1007/s10620-005-9057-1
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
resolves10.1007/s10120-012-0150-9
HER2 expression and its clinicopathological features in resectable gastric cancer
resolves10.1186/1471-2407-8-363
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
resolves10.1007/s00268-009-0142-z
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
The 5 references without a DOI — listed, not checked
no DOI — not checkedNormanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-257.
no DOI — not checkedKapitanović S, Radosević S, Slade N, Kapitanović M, Andelinović S, Ferencić Z, Tavassoli M, Spaventi S, Pavelić K, Spaventi R. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000;126:205-211.
no DOI — not checkedJacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-1987.
no DOI — not checkedYano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.
no DOI — not checkedAdams KF. Post hoc subgroup analysis and the truth of a clinical trial. Am Heart J 1998;136:753-758.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3748/wjg.v22.i23.5406"><img src="https://citestamp.com/citestamped/10.3748/wjg.v22.i23.5406/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3748/wjg.v22.i23.5406)